Annovis Bio announced today the completion of patient enrollment for its phase III Parkinson’s Disease trial in a record nine months

[Farooqji]

prnewswire.com/news-release...

[jeffreyn]

"The study is expected to conclude in November with top-line assessment data available by the end of the year."

[Boscoejean]

In reading about this research , I thought that the fact that the study was being conducted in so many locations would be helpful in finding participants and making it convenient for them to enroll. Another advantage to this strategy is that they probably get a variety of patients participating.

[ZebraDoodle]

clinicaltrialsarena.com/new...

[gaga1958]

I am in this trial, started 6 weeks ago. So far, no changes good or bad.

[Farooqji in reply to gaga1958]

Thanks for sharing.

[Ctime]

I go for my end of trail assessment after 6 months this week. It does not appear that there will be an open label extension until next year but I will post if I find out anything different

[Voykky in reply to Ctime]

Did you notice any changes during the trial?

[Ctime in reply to Voykky]

Voykky,

I am unfortunately circumspect about providing direct answers to that question. If as Farooqji suggests below that slowing disease progression is a measure of success, I am not qualified to asses that. Of course, I also don't know and perhaps may never (or not for a long time) know if I was on placebo or not.

I will say that I have not seemed to come to any harm, nor have I been miraculously cured. There are changes in my condition but if these are normal ebb and flow, I really don't know. My personal symptoms are relatively mild, 2 years post diagnosis, so it might be hard to see any dramatic results.

If it is ethical to post more, I am happy to provide more details, perhaps in conjunction with others later this year.

[Voykky in reply to Ctime]

Thanks, i do understand. Wish you the best.

[Ctime in reply to Ctime]

FWIW, I finished the Bunanetap trial yesterday. It was a very good experience and I would recommend a trial for those that can get involved. In the US, it is a way to get a lot of personal care for very little money. 😀 Plus it was personally rewarding. The clinic where I participated enrolled 30 patients in the Bunanetap PD trial and is now enrolling Alzheimer's patients.

The clinic gave the first dose to their last enrollee in the PD trial last week so that is consistent with a trial conclusion in mid November. Hopefully some initial results shortly thereafter. I was told there would be no open label before Q1 2024, earliest. This is all consistent with what we heard in the Annovis investor online meeting. I was told that it might be a year before I learn if I was on placebo or the drug. Apparently there are very few problems or adverse effects with patients in the trial.

Onward!, Ctime

[Farooqji in reply to Ctime]

thanks for sharing. Wish you best of luck!

[Farooqji]

I was listening to the ANNOVIS BIO CEO in which she told that the improvement doesn't mean that subsiding the symptoms. Rather she explained that the slowing down of worsening of symptoms are considered as improvements. In their trial they are following the measurement philosophy based on speed of deteriorating the symptoms

[Farooqji in reply to Farooqji]

This has made me skeptical about the chances of success

[jeffreyn]

See also their recently-updated slidepack (June 2023).

irpages2.eqs.com/download/c...